Design, synthesis and biological evaluation of tacrine-1, 2, 3-triazole derivatives as potent cholinesterase inhibitors. Issue 1 (13th December 2017)

• Record Type: Journal Article
• Authors: Wu, Gaochan; Gao, Yun; Kang, Dongwei; Huang, Boshi; Huo, Zhipeng; Liu, Huiqing; Poongavanam, Vasanthanathan; Zhan, Peng; Liu, Xinyong
• Is Part Of: MedChemComm. Volume 9:Issue 1(2018)
• Page Start: 149
• Page End: 159
• Publication Date: 2017-12-13
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19
• DOI: 10.1039/c7md00457e
• Languages: English
• ISSNs: 2040-2503

Abstract

Abstract : We report herein the design and synthesis of a series of 11 novel tacrine-1, 2, 3-triazole derivatives via a Cu(i )-catalyzed alkyne–azide 1, 3-dipolar cycloaddition (CuAAC) reaction. Abstract : We report herein the design and synthesis of a series of 11 novel tacrine-1, 2, 3-triazole derivatives via a Cu(i )-catalyzed alkyne–azide 1, 3-dipolar cycloaddition (CuAAC) reaction. The newly synthesized compounds were evaluated for their inhibition activity against Electrophorus electricus acetylcholinesterase (AChE) and horse serum butyrylcholinesterase (BChE) as potential drug targets for Alzheimer's disease (AD). Among the designed compounds, compound8a2 exhibited potent inhibition against AChE and BChE with IC50 values of 4.89 μM and 3.61 μM, respectively. Further structure–activity relationship (SAR) and molecular modeling studies may provide valuable insights into the design of better tacrine-triazole analogues with potential therapeutic applications for AD.